Skip to content

Versicolor Treatment

Efficacy of topical terbinafine and ketoconazole in pityriasis versicolor

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201107184808N4
Enrollment
100
Registered
2011-11-13
Start date
2010-04-19
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

versicolor. Pityriasis versicolor

Interventions

Intervention 1: CONTROL: ketoconazol 2% cream .the creams are used topically twice a day for 2 weeks. Intervention 2: INTERVENTIONAL:terbinafin hydrochloride 1% cream.the creams are used topically tw
Treatment - Drugs
CONTROL: ketoconazol 2% cream .the creams are used topically twice a day for 2 weeks.
INTERVENTIONAL:terbinafin hydrochloride 1% cream.the creams are used topically twice a day for 2 weeks.

Sponsors

KURDISTAN University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria are:Age above 14 years; KOH positive ; involvement of less than 10% of the body surface by the lesions. Exclusion criteria are:Extensive involvement of the skin ; topical or systemic antifungal therapy; and use of steroid or antibiotic within the last month before starting the study;pregnancy or likelihood of pregnancy; lactation and the patients who are not cooperative

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
PTRIASIS versicolor. Timepoint: After completion of the treatment course the patients will be requested to refer for follow up after 1 weeks, one month and two months of treatment or in case of recurrence of the lesions. Method of measurement: Skin smears are taken by a scalpel or a tape and will be examined by a pathologist for the presence of mycelium. The patients with positive smears will enter into the study.

Secondary

MeasureTime frame
LOCAL complications. Timepoint: after 2 weeks, one month and two months of treatment. Method of measurement: by a physician or patient self-report.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDR FAROKH RAD

MEDICAL UNIVERSITY OF KURDISTAN

MOZH.ZAREI@MUK.AC.IR+98 87 1613 1278

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026